SutroVax, a recently established biopharmaceutical vaccine company, announced on Thursday the completion of a $22 million Series A financing round. This round was led by Abingworth, the international investment group, with participation from Longitude Capital, Roche Venture Fund and CTI Life Sciences Fund.
SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma’s Xpress CF™ and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively. The recently secured funds will go towards the company’s advancing multiple vaccines in its pipeline through pre-clinical proof of concept.
Grant Pickering, CEO of SutroVax, shared:
“Our platform technology is already industrialized and uniquely enables precise site-specific conjugation and production of protein antigens that are beyond the reach of current technologies. We intend to develop best-in-class vaccines to address an array of high-impact infectious diseases.”
Kurt von Emster, Managing Partner of Abingworth, noted:
“Abingworth is pleased to work with the talented team at SutroVax and this prestigious group of co-investors.”
As part of the financing, Kurt von Emster will become interim Chairman at SutroVax. In addition, Patrick Enright and Dr. Tracy Saxtonfrom Longitude Capital and Roche Venture Fund, respectively, will join Grant Pickering and William Newell, CEO of Sutro Biopharma, on the board of directors.
William Newell, CEO of Sutro Biopharma, added:
“It’s gratifying to see another high-value cache of applications gain momentum leveraging the platform and its well-developed infrastructure, including our large-scale cGMP facility.”
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!